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bstract
RAS belongs to the guanosine 5′-triphosphate (GTP)-binding proteins’ family, and oncogenic mutations in codons 12, 13, or 61 of RAS
amily occur in approximately one third of all human cancers with N-RAS mutations found in about 15–20% of melanomas. The importance
f RAS signaling as a potential target in cancer is emphasized not only by the prevalence of RAS mutations, but also by the high number
f RAS activators and effectors identified in mammalian cells that places the RAS proteins at the crossroads of several, important signaling
etworks. Ras proteins are crucial crossroads of signaling pathways that link the activation of cell surface receptors with a wide variety of
ellular processes leading to the control of proliferation, apoptosis and differentiation. Furthermore, oncogenic ras proteins interfere with
etabolism of tumor cells, microenvironment’s remodeling, evasion of the immune response, and finally contributes to the metastatic process.
fter 40 years of basic, translational and clinical research, much is now known about the molecular mechanisms by which these monomeric
uanosine triphosphatase-binding proteins promote cellular malignancy, and it is clear that they regulate signaling pathways involved in the
ontrol of cell proliferation, survival, and invasiveness. In this review we summarize the biological role of RAS in cancer by focusing our
ttention on the biological rational and strategies to target RAS in melanoma. 2014 Elsevier Ireland Ltd. All rights reserved.eywords: NRAS; Melanoma; Prognostic; Predictive; Resistance
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Ras proteins are crucial crossroads of signaling path-
ays that link the activation of cell surface receptors
ith a wide variety of cellular processes leading to the
ontrol of proliferation, apoptosis and differentiation. Fur-
hermore, oncogenic ras proteins interfere with metabolism
f tumor cells, microenvironment’s remodeling, evasion of
he immune response, and finally contributes to the metastatic
rocess.
The importance of RAS signaling as a potential target in
ancer is emphasized not only by the prevalence of RAS
utations, but also by the high number of RAS activators
nd effectors identified in mammalian cells that places the
AS proteins at the crossroads of several, important signaling
etworks.
After 40 years of basic, translational and clinical research,
uch is now known about the molecular mechanisms by
hich these monomeric guanosine triphosphatase-binding
roteins promote cellular malignancy, and it is clear that they
egulate signaling pathways involved in the control of cell
roliferation, survival, and invasiveness. In this review we
ummarize the biological role of RAS in cancer by focusing
ur attention on the biological rational and strategies to target
AS in melanoma.
.  Historical  perspective  on  NRAS  in  cancer  and  a
ocus on  melanoma
Thirty years ago a pioneering study demonstrated that
mall fragments of DNA from human cancer-derived cells
ould induce malignant characteristics in mouse fibroblasts
1]. The cellular homolog of an oncogene found in the Harvey
at sarcoma retrovirus (H-RAS) was identified as the DNA
equence responsible for such malignant transformation. A
ew step in tumor biology had been put in place: this was the
rst demonstration that human tumors contained activated
ncogenes, related to those picked up by retroviruses from
heir host genomes [2,3]. Gene sequencing revealed that the
ifference between the wild-type (wt) human H-RAS gene
nd the oncogenic form found in tumors was a single point
utation. Subsequently, three RAS genes and correspond-
ng proteins were described: N-RAS (neuroblastoma-RAS),
-RAS and K-RAS (Kirsten-RAS) [4–6].
RAS belongs to the guanosine 5′-triphosphate (GTP)-
inding proteins’ family. When acted upon by specific
actors, such as extracellular ligands that bind specific mem-
rane receptors, these proteins cycle between an activated
nd inactivated form, RAS-GTP and RAS-GDP, respec-
ively [7]. Activation requires dissociation of protein bound
DP, a process that is accelerated by guanine nucleotide-
xchange factors (GEFs). This switch-on process involves the
eversible exchange of GDP for GTP. The switch-off process
s entirely different and involves hydrolysis of GTP to GDP,
he guanosine triphosphatase (GTPase) reaction, which is
asically irreversible. This process is accelerated by GTPase
ctivating proteins (GAPs) (Fig. 1a).
d
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In physiological conditions, RAS proteins are tethered to
he inner cell membrane, coupling growth factor receptors
o downstream signaling pathways and regulate important
ellular functions such as cell growth, proliferation, and sur-
ival. Much is now known about the molecular mechanisms
y which these monomeric guanosine triphosphatase-binding
roteins promote cellular malignancy, and it is clear that they
egulate signaling pathways involved in the control of cell
roliferation, survival, and invasiveness.
Mutations at positions 12, 13, or 61 of the H-RAS, N-
AS, and K-RAS impair the GTPase activity of the carrier
AS proteins and lock them into a constitutively activated
tate in which they elicit downstream effectors, even in the
bsence of ligands that bind specific membrane receptors [8].
his peculiar oncogenic activation – disabling the enzymatic
ctivity – differentiates RAS from other oncogenic kinases
uch as EGFR or B-RAF, which are typically mutated to
roduce a hyperactive enzyme.
The importance of RAS signaling as a potential target in
ancer is emphasized not only by the prevalence of RAS
utations, but also by the high number of RAS activators
nd effectors identified in mammalian cells that places the
AS proteins at the crossroads of several, important signaling
etworks (Fig. 1b).
The first RAS effector identified is the RAF ser-
ne/threonine kinase [9–12]. Activation of RAF initiates a
hosphorylation cascade that progresses through MEK and
RK (p42/p44 MAPK), and ultimately leads to fine adjust-
ents in downstream targets that regulate cell proliferation,
urvival, and differentiation [13]. A second RAS effector
s the p110 catalytic subunit of the phosphatidylinositol 3-
inase (PI3K) [14]. Phosphorylation of phosphatidylinositol
y PI3K brings the AKT serine/threonine kinase to the plasma
embrane, where it becomes activated and transmits down-
tream signals to regulate cell survival, protein synthesis, and
etabolism [15]. RAF and PI3K are also commonly mutated
n melanoma, suggesting that these proteins might be the
rimary oncogenic effectors of RAS signaling [16].
Interestingly, while mutations in RAF and RAS are gen-
rally mutually exclusive, this is not the case for PI3K
utation. These biological differences suggest that endoge-
ous levels of activated RAS do not efficiently activate PI3K
ignaling, while RAS and RAF mutations appear functionally
quivalent. Another explanation is that the RAS/RAF double
utation is lethal for the cell whereas RAS/PI3K are not.
Since oncogenic mutations in codons 12, 13, or 61 of
AS family occur in approximately one third of all human
ancers with N-RAS mutations found in about 15–20% of
elanomas, RAS and the signaling pathways under its con-
rol have been kept firmly in focus as therapeutic targets
Fig. 2). However, after 40 years of research, many problems
emain open. First, what has prevented the development of
rugs against RAS?
Several factors have hampered the development of
herapies that are able to inhibit RAS in a specific and
ffective way: (1) the high affinity of RAS for GTP; (2)
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Fig. 1. (a) Mechanism of RAS activation. Receptor tyrosine kinase (RTK)-mediated activation requires dissociation of protein bound GDP, a process that is
accelerated by guanine nucleotide-exchange factors (GEFs). This switch-on process involves the reversible exchange of GDP for GTP. The switch-off process
is entirely different and involves hydrolysis of GTP to GDP, the guanosine triphosphatase (GTPase) reaction, which is basically irreversible. This process
is accelerated by GTPase activating proteins (GAPs). (b) Effectors identified in mammalian cells that place the RAS proteins at the crossroads of several,
important signaling networks. (TIAM1: T-cell lymphoma invasion and metastasis 1; PI3K: phosphoinositide 3-kinase; PDK1: phosphoinositide-dependent
kinase-1; ERK: extracellular regulated kinase; RALGDS: RAL guanine nucleotide dissociation stimulator; PLD: phospholipase D; PLC: phospholipase C;
P
h
i
s
t
c
s
c
v
R
r
p
l
s
t
“
“
e
“
w
t
e
2
w
a
p
m
t
i
pKC: protein kinase C).
igh intracellular concentrations of GTP; (3) the attempt to
nhibit farnesylation, a key posttranslational modification
tep of RAS that is essential for RAS function, through
he farnesyltransferase inhibitors (FTIs), was ineffective in
linical trials; (4) targeting mutant N-RAS with siRNA is
till limited to preclinical models because of the signifi-
ant challenge in delivering antisense oligonucleotides in
ivo.
In this review we summarize the biological role of
AS in cancer by focusing our attention on the biological
ational and strategies to target RAS in melanoma. For this
urpose, we performed an extensive “Medline” and Cancerlit
iterature review (1995–2012). Various combinations of
earch terms were used depending on the requirements of
he database being searched. These terms included “RAS”,
MAPK”, “target therapy”, “MEK” in combination with
cancer patients”, “melanoma”, “incidence”, “pathogen-
sis”, “management”, “cancer”, “tumors”, “resistance”,
trials”, “prospective”, “phase”, “retrospective”. In addition,
2
oe manually researched all relevant review articles and
he references of the retrieved papers. Finally, trials were
xcluded if relevant data could not be extracted.
. Biological  functions  of  NRAS
Ras proteins are crucial crossroads of signaling path-
ays that link the activation of cell surface receptors with
 wide variety of cellular processes leading to the control of
roliferation, apoptosis and differentiation (Fig. 3). Further-
ore, oncogenic ras proteins interfere with metabolism of
umor cells, microenvironment’s remodeling, evasion of the
mmune response, and finally contributes to the metastatic
rocess..1.  Cell  proliferation
Three decades ago Feramisco et al. demonstrated that
ncogenic, mutated forms of ras proteins when introduced
110 M. Mandalà et al. / Critical Reviews in Oncology/Hematology 92 (2014) 107–122
Fig. 2. Potential therapeutics targets in melanoma.
Fig. 3. Ras proteins are crucial crossroads of signaling pathways that link the activation of cell surface receptors with a wide variety of cellular processes
leading to the control of proliferation, apoptosis and differentiation.
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y microinjection into a variety of somatic cells determine
ramatic morphological changes followed by transient cell
roliferation [17]. Proliferation is a check and balances
rocess, being the result of different stimuli, that elicit or
nhibit cell cycle [18]. Oncogenic RAS fuels cell prolifera-
ion through four distinct biological mechanisms that carry
he balance of different stimuli to hang on the side of the cell
ycle: upregulation of growth factors, expression of growth
actor receptors, upregulation of integrins that promote pro-
iferation and downregulation of anti-proliferative signals.
hese complex and still unclarified mechanisms lead to acti-
ation of several transcription factors such serum response
actor (SRF), JUN, activating transcription factor 2 (ATF2)
nd nuclear factor-B (NF-B) [19,20]. In turn, these factors
rigger the expression of cyclin D1 [21]. The expression of the
1 cyclin seems a crucial determinant of RAS-induced trans-
ormation. It has been reported that cyclin D1-deficient mice
re resistant to developing epithelial tumors that are induced
y the HRAS oncogene. Pharmacological interference with
yclin D1 or cyclin-dependent kinase inhibitors (CKIs), such
s p27 and p21, which would otherwise associate with and
nhibit cyclin-dependent kinases (CDKs), could be an excit-
ng avenue of cancer research in the coming years.
.2.  Suppression  of  apoptosis
Oncogenic RAS may have both pro-apoptotic and anti-
poptotic functions. The anti-apoptotic function of oncogenic
AS is mediated by several effector pathways, including
he RAS–PI3K and the RAS–RAF pathway. Both pathways
ave been implicated in phosphorylating and inactivating
he pro-apoptotic protein BCL-2-associated agonist of cell
eath (BAD). There is evidence that RAS is implicated in
oth the development and maintenance of melanoma. In
xperimental models, melanoma genesis and maintenance
re strictly dependent upon expression of HRas V12G and on
he opposite HRas V12G down-regulation results in clinical
nd histological regression of primary and explanted tumors
22]. The initial stages of regression involved marked apopto-
is in the tumor cells and host-derived endothelial cells. These
ata clearly support the hypothesis of an oncogenic RAS-
riven erosion of the apoptotic pathways and its contribution
o melanoma development.
.3.  Metabolism
RAS-driven activation of MAPK and PI3K effector path-
ays stimulate mTOR activity which, in turn, up-regulates
he hypoxia-inducible factor 1  (HIF1), which is well rec-
gnized for its ability to stimulate a glycolytic shift [23]. RAS
ependent upregulation of HIF1  enhances the transcription
f the glucose transporter GLUT1, thus conferring cells with
n increased capacity to take up glucose. In addition, onco-
enic RAS leads to an increase in the levels of key glycolytic
nzymes [24]. Thus, oncogenic RAS directly contributes to
etabolic reactions that stimulate the use of glucose as an
m
t
slogy/Hematology 92 (2014) 107–122 111
nabolic substrate in producing building material for cellular
rowth. Oncogenic RAS interfaces with cellular metabolism
nd this interaction increases ultimately the glycolytic rate
nd cellular viability, supporting tumor growth in vivo [25].
.4.  Remodeling  the  microenvironment
RAS activation sustains pro-angiogenic processes through
odulation of endothelial growth factors levels, enhance-
ent of local inflammation and stromal remodeling [26].
AS upregulates VEGFA via multiple effectors, includ-
ng, HIF1, cyclooxygenase 2 (COX2) and prostaglandins’
roduction [27]. Furthermore, RAS-mediated production of
ro-inflammatory cytokines, such as IL-6 and IL-8, has
merged as another contributor to the induction of angiogen-
sis [28]. Finally, upregulation of matrix metalloproteinase 2
MMP2), MMP9 and urokinase-type plasminogen activator
uPA) has been described [29].
.5.  Evasion  of  the  immune  response
Oncogenic RAS can disrupt antitumor immunity by
ssentially two mechanisms: first, by reducing the surface
xpression of antigen-presenting major histocompatibility
omplexes (MHC) on tumor cells, resulting in decreased
mmunogenicity of the RAS-transformed cells [30]. Second,
y overcoming host-protecting adaptive immune responses
31]. Upon oncogenic RAS expression, the recruitment of
mmunosuppressive regulatory T cells and myeloid-derived
uppressor cells at tumor site may lead to a compromised
ntitumor immune response [32].
.6.  Metastasis
Metastasis is a multi-stage process involving a multitude
f cellular activities such as cancer cell motility, intrava-
ation, transit in the blood or lymph vessels, extravasation
nd growth at a new site. RAS promotes these processes by
ngaging a diverse and broad platform of effector mecha-
isms. Oncogenic RAS induces alterations in cell–cell and
ell–matrix interactions and the acquisition of a migratory
henotype ultimately contributing to the metastatic process.
ncogenic RAS reduces E-cadherin levels and induces the
estabilization of E-cadherin – -catenin complexes and
he  catenin relocalization [33]. In addition, oncogenic
AS contributes to the enhanced motility of tumor cells by
ffecting changes in the polymerization, organization and
ontraction of actin; the polymerization and/or stability of
icrotubules; and the transcriptional regulation of mitogenic
ene products [34]. Oncogenic RAS protects tumor cells from
atrix deprivation-induced apoptosis, or anoikis thereby con-
ributing to their capacity of migration through the circulatory
ystem [33–35].
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.  NRAS  in melanocytic  cell  neoplasms
One of the unresolved issues concerning the oncogenic
ctivation of RAS pertains to whether specific oncogenic out-
uts are driven by mutations in a particular RAS isoform.
his hypothesis is supported by the well-recognized non-
andom distribution pattern of activated isoforms of RAS
mong different cancer types.
NRAS mutations have been found in approximately
5–20% of human melanomas while HRAS and KRAS
utations are rare (1%) [36]. A rational explanation for the
reater occurrence of NRAS mutations relies on distinct dif-
erences between the signaling capabilities of NRAS and
RAS in melanocytes [37]. When the transformation effi-
iencies of mutant NRAS and KRAS were compared in
mmortal, non-transformed Ink4a/Arf-deficient melanocytes,
t was shown that in contrast to KRAS mutation, NRAS
utation leads to increased cellular proliferation and is more
otently tumorigenic [37]. Furthermore, NRAS mediates
ctivation of both MAPK and PI3K/AKT/MYC signaling.
pecifically, although both NRAS and KRAS efficiently
ctivate the classical MAPK pathway, only NRAS effec-
ively prevents glycogen synthase kinase3 (GSK3)-mediated
hosphorylation of Myc via PI3K/AKT, which results in
nhanced activity of endogenous Myc protein [37]. In con-
rast to KRAS, NRAS and HRAS also show a more potent
ctivation of PI3K/AKT likely due to the fact that both
RAS and HRAS colocalize to lipid rafts, whereas KRAS
s excluded from lipid rafts and localizes to the disordered
lasma membrane [38], resulting in a less efficient activation
r a limited access to a defined subset of downstream effector
roteins.
There is a great debate whether specific RAS isoforms dic-
ate specific clinico-pathological melanocytic cell neoplasms.
n extraordinarily high NRAS mutation frequency seems to
e characteristic of medium-sized (≥1.5 cm) and large-giant
ongenital nevi whereas common acquired nevi and Spitz
evi have rare NRAS mutations (4.6% and 4%, respectively)
39].
The frequency of NRAS mutations in medium-sized con-
enital nevi is 64–70% [39–41] and raises to 94.7% in
arge-giant congenital nevi where it has been recently rec-
gnized as the sole recurrent somatic mutation [42]. It has
een suggested that NRAS mutations exert stronger growth
ignals, resulting in the formation of larger nevi than those
inked to BRAF mutations [43]. In contrast, small congenital
evi (<1.5 cm) are genetically similar to common acquired
evi and tend to show a lower incidence of NRAS mutations
nd higher incidence of BRAF mutations [40]. In addition,
t has been reported that nevi that display histological fea-
ures frequently found in nevi present at birth (so-called
congenital pattern nevi”) but lack a definitive history of
resence at birth showed only 25% of NRAS mutations and
1% of BRAF mutations [44]. NRAS mutations were also
ound in 48% to 70% of proliferative nodules that developed
ithin congenital nevi early in life, but the presence of such
t
m
(
elogy/Hematology 92 (2014) 107–122
utations does not seem to confer an increased risk of malig-
ant transformation [44,45].
Recently, different studies have demonstrated that early
mbryonic/post zygotic somatic mutations in the NRAS
ene are implicated in the development of neurocutaneous
elanocytosis, a rare congenital disorder, in which affected
atients have an increased number of melanocytes in the lep-
omeninges and the skin, with a large congenital melanocytic
evus usually associated with so-called “satellites” in the
icinity, and childhood melanoma of the central nervous
ystem [46–48]. In line with these observations, recently it
as been shown that primary melanoma of the CNS in chil-
ren carries oncogenic mutations in NRAS, unlike primary
elanoma of the central nervous system in adults, in which
RAS is not a common driver oncogene [46].
So-called “dysplastic nevi” do not seem to carry NRAS
utations [49–51]. However, in another study 5/7 “dysplas-
ic nevi” from individuals with a hereditary predisposition
o melanoma (who carried germline CDKN2A mutations)
ere reported to be NRAS mutated and it was suggested
hat NRAS mutations are implicated during early melanoma
evelopment [52]. Overall, given the limited number of cases
nalyzed and the lack of interobserver agreement for the
orphology-based diagnosis of “dysplastic nevi” it is too
arly to draw significant conclusions. A recent study has
hown that nevus-associated melanomas show a similar fre-
uency of BRAFV600-and NRASQ61-mutations compared
o published reports of melanomas of the skin in general [53].
uch results do not support the concept that oncogenic BRAF
r NRAS mutations play a major role in the development of
elanoma from nevi and do not sustain the multistep theory
f melanoma progression from a benign melanocytic nevus
hrough “dysplastic nevus” and eventually to melanoma [53].
RAS has been extensively investigated in melanoma and
everal studies have assessed whether specific RAS isoforms
orrelate with race, pattern of sun exposure, clinical presen-
ation, and conventional morphological features, which are
ommonly reported in histopathological reports.
NRAS is mutated in approximately 15–20% of primary
utaneous melanomas in Caucasian patients [54–58]. In black
fricans and Asian populations there is a lower frequency
12% and 7.2%, respectively) [59,60]. Patients with NRAS-
utated melanomas were reported to be older in comparison
ith individuals with BRAF-mutated tumors [61] although in
 recent meta-analysis on 31 studies involving 1972 patients,
o association between age and NRAS mutations was found
55]. Similarly, no correlation was found between gender and
RAS mutations [58].
In most studies, NRAS mutation was significantly more
requent in melanomas arising in chronic sun-damaged skin
55,62]. The incidence of the NRAS mutation according to
umor site was highest in the extremities (25%), followed by
he face or scalp (18%) and trunk (18%) [55,61,63]. NRAS
utations have also been found in conjunctival melanomas
18% frequency) [63], sinonasal melanomas (22%) [65],
sophageal melanomas (37.5%), including mutations in exon
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, which is a rare mutation site for cutaneous melanoma
66]. Interestingly, melanoma of unknown primary sites
howed NRAS mutations in 32% of cases associated with
igh somatic mutation rates, high ratios of C>T/G>A transi-
ions, and a 45% of BRAF mutations, collectively indicating
 mutation profile consistent with cutaneous sun-exposed
elanomas [67].
NRAS mutations are overall more frequently evident in
atients with nodular melanoma [55]. From 25% to 31%
f NRAS mutations occurred in this melanoma subtype
55,59,68]. A higher incidence of NRAS mutations was found
n non-acral fast growing melanomas in comparison with
on-fast growing melanomas (26.5 versus 12.1%) [69].
While in some studies NRAS mutated melanomas were
eported to be significantly thicker and higher Clark’s level
han wt tumors [61,62,64,68] other reports could not con-
rm any association between NRAS mutation and tumor
hickness [70,71]. Ulceration was reported to be lower in
RAS-mutated tumors in comparison to BRAF mutated
umors (9.7 versus 22.4%, respectively) [63] but no obvious
ffect of mutational status on the presence of ulceration was
eported by others [68]. Melanomas harboring NRAS muta-
ions have shown greater mitotic rates than BRAF mutant
elanomas [63,68].
In conclusion, the retrospective nature of the studies and
he heterogeneity of patients’ populations may explain the
ifferent results obtained so far, and it should be acknowl-
dged that phenotypic-genotypic correlations in melanoma
s still a work in progress.
.  NRAS:  prognostic  or  predictive  biomarker  in
elanoma? a critical  analysis  of  current  literature
The prognostic and predictive significance of NRAS in
elanoma is still a matter of intense debate.
A biomarker is, by definition, an objectively measured
nd evaluated parameter that provides information on the
atural history of a specific disease, its pathogenic process
r on pharmacological responses to a specified therapeutic
ntervention. A prognostic biomarker provides information
n overall cancer outcome, regardless of therapy. In the med-
cal literature two types of prognostic biomarkers have been
eported: biomarkers that give information on recurrence in
atients who receive curative treatment and those that cor-
elate with the median overall survival (OS) in patients with
etastatic disease. According to a NIH Consensus Confer-
nce, a clinical useful prognostic marker must be a proven
ndependent, significant factor, that is easy to determine and
nterpret and has therapeutic consequences [72].
Prognostic biomarkers that provide information on the risk
f relapse are important not only to better stratify patients in
linical trials but also to spare many patients the treatment-
elated toxicity without compromising survival. A biomarker
ith predictive value gives information on the effect of a
herapeutic intervention in a patient. Two types of predictive
m
m
t
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iomarkers have been reported: (1) upfront and (2) early pre-
ictive markers. The first can be used for patient selection
nd the second provides information early during therapy.
he latter biomarker is less useful than the former because
oes not provide reliable and useful information to select the
est strategy to be adopted before starting therapy.
.1.  Is  NRAS  a prognostic  biomarker  in  melanoma?
Several studies have been carried out to examine whether
utations in NRAS confer different pathological features and
linical behavior. The effect of these mutations on clinical
utcome remains uncertain [59,61,73,74]. Table 1 summa-
izes most important studies on the prognostic role of NRAS
n melanoma [63,68,74–79,61,80–83]. The majority of these
tudies have been retrospective in nature, and most of them
ncluded patients with recurrent or metastatic disease.
When OS was measured from the time of primary tumor,
RAS mutations were found to have no impact on OS
59,63,61]. Akslen et al. evaluated 51 primary nodular
elanomas. In this retrospective study NRAS mutation was
ound in 27% of patients [82]. RAS mutation was not associ-
ted with tumor cell proliferation by Ki-67 expression, tumor
hickness, microvessel density, or vascular invasion, and there
ere no differences in patient survival [82].
In an attempt to correlate BRAF and NRAS mutational
tatus with features known to influence tumor behavior,
ncluding age, gender, Breslow depth, Clark level, mitotic
ate, the presence of ulceration, and AJCC staging, Eller-
orst et al. performed a study on 223 microdissected primary
elanomas [63]. Patients whose tumors carried either muta-
ion presented with more advanced stages compared to
atients with wt tumors, and specifically, were more likely to
ave Stage III disease at diagnosis. BRAF and NRAS muta-
ions did not influence survival. Furthermore, in this study
urvival did not differ between Stage III patients whose pri-
ary tumors do or do not carry mutations, even though the
utated tumors tended to produce larger volume nodal dis-
ase [63].
Recently, Devitt et al. reported data obtained from a
rospective cohort of 249 patients [67]. When compared to wt
RAS patients, multivariate analysis of melanoma-specific
urvival identified NRAS mutations as an adverse progno-
tic factor. However in the multivariate analysis, there was
o evidence that NRAS mutation was neither an independent
redictor of relapse free survival (RFS) nor of OS [68].
However, in two studies where OS was measured from the
ime of biopsy of advanced disease, NRAS mutations were
ssociated with improved OS when compared to tumors with
RAF mutations or both BRAF/NRAS wt tumors [73,74].
Mann et al. performed a comprehensive clinico-
athological assessment of fresh-frozen macroscopic nodal
etastases and the preceding primary melanoma, somatic
utation profiling, and gene expression profiling to iden-
ify determinants of outcome in 79 melanoma patients [81].
he authors found that the absence of BRAF mutation or
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Table 1
Summary of most significant studies addressing the prognostic significance of NRAS mutations in melanoma.
RAS mutation and melanoma prognosis
Author Patients no. Stage Site of primary
melanoma
Genes Exons PFS OS
Demunter (2001) [75] 81 All stages Skin NRAS 1 p = 0.0130 –
Omholt (2002) [78] 72 All stages Skin NRAS 2
3
– NS
Houben (2004) [76] 174 All stages Skin BRAF 15
11
NS NS
p = 0.02a
NRAS 1
2
Akslen (2005) [81] 57 All stages Skin BRAF 15
11
– NS
NRAS 2
1
Edlundh-Rose (2006)
[79]
219 NA Skin BRAF 15
11
– NS
NRAS 2
Ugurel (2007) [73] 109 III
IV
Skin
Mucosa
Occult
NA
BRAF 15
11
– p = 0.006
NRAS 2
1
Ellerhorst (2010) [62] 223 I–III Skin BRAF 15 – NS
NRAS 2
Devitt (2011) [67] 244 I–III Skin BRAF 15 – p = 0.04
(MSS)
NRAS 3
Jakob (2012) [77] 667 All stages Skin
Mucosa
Uvea
Occult
BRAF 15 – p = 0.004
NRAS 1
2
Mann (2012) [80] 79 III Skin BRAF 15 – NS
NRAS 2
Bucheit (2013) [61] 438 IV Skin
Mucosa
Soft parts
Occult
BRAF 15 – NS
NRAS 1
2
Birkeland (2013) [74] 85 III
IV
Skin
Mucosa
Uvea
Occult
NRAS 3 p < 0.01 p < 0.001
Ekedahl (2013) [82] 203 IV Skin BRAF 15 – p = 0.25
NRAS 2
OS: overall survival; PFS: progression free survival; MSS: melanoma-specific survival; NS: not significant.
a
N
s
s
d
wOS from metastasectomy.
RAS mutation was independently associated with better
urvival. Furthermore, a 46-gene expression signature with
trong overrepresentation of immune response genes was pre-
ictive of better survival; in the full cohort, median survival
i
Nas >100 months in those with the signature, but 10 months
n those without.
Recently, in a retrospective study, Jacob et al. tested for
RAS 677 patients with metastatic melanoma to identify
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Table 2
Studies reporting on RAS mutations as predictive biomarkers in melanoma.
RAS as predictive biomarker in melanoma
Author Patients
no.
Stage Site of
primary
melanoma
Genes Mutations Drug (s) OS PFS TTP CCR/CB
Banerji (2008)
[83]
6 NR NR BRAF V600E 17-AAG NR – NR NR
NRAS G13D 17-AAG
Joseph (2012)
[84]
208 IIIc
IV
NR BRAF V600 HD IL2 NS
NS
NS
NS
– –
p = 0.05
NRAS G12
G13
Q61
HD IL2
Birkeland (2013)
[74]
85 III
IV
Skin
Mucosa
Uvea
Occult
NRAS G12
G13
DTIC p < 0.001 NS – NS
Patelet (2013) [85] 18 III
IV
Skin BRAF V600E
R603
S. +/−DTIC,
TXT, E. or T.
NR – NS NS
NRAS Q61R
Q61K
G12S
S. +/−DTIC,
TXT, E. or T.
17-AAG: HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin; DTIC: dacarbazine; CB: clinical benefit: objective response or stable disease recorded
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[ months after DTIC treatment; HD IL2: high-dose interleukin 2; CRR: cl
XT.: docetaxel; E.: erlotinib; T.: temsirolimus.
ignificant associations of mutation with tumor and patient
haracteristics and with survival from the diagnosis of stage
V disease [78]. Tumor mutation status was associated with
he risk of central nervous system involvement at the diag-
osis. Patients with NRAS mutations had a median survival
f 8.2 months from stage IV diagnosis, which was shorter
han the median survival of wt patients (15.1 months). At
ultivariate analysis, after adjusting for age, sex, metastatic
ite, serum lactate dehydrogenase level, NRAS mutation was
ndependently associated with decreased OS.
Overall, the results published so far are heterogeneous
n terms of patients’ selection criteria and methodology.
pecifically, difficulties in comparing results arise from the
ollowing considerations: (i) most of the available data are
etrospective; (ii) patients with different tumor stages have
een evaluated; (iii) primary or metastatic sites have been
ested; (iv) different tumor histotypes have been included.
Hence, there is no definitive evidence that NRAS muta-
ion is prognostic in patients with limited radically resected
isease (stages I–III) or in metastatic setting. Furthermore,
ost of the observations have been conducted in Caucasian
opulations with scarcity of data from other geographic areas
e.g. Asian).
.2.  Is  NRAS  a predictive  biomarker  in  melanoma?The RAS mutational status does not give information on
he effect of a therapeutic intervention in a patient, hence it is
ot a predictive marker either upfront or as early predictive
p
w
ssponse rate; TTP: time to progression; NR: not reported; S.: selumetinib;
arker. Table 2 includes studies addressing the predictive
ignificance of NRAS mutations in melanoma [75,84–86].
So far, several different strategies of directly targeting
AS have not resulted in effective therapeutics. There is evi-
ence that some NRAS-mutated cell lines are sensitive to
EK inhibition in vitro [87]. However, in this model, the
ensitivity to the MEK inhibitor of N-RAS mutated cells was
ignificantly lower than those harboring BRAF mutation.
The lower activity of MEK inhibitors in N-RAS-mutated
n comparison with BRAFV600-mutated melanoma cells
ay be explained by the complexity of pathways with which
AS interacts within the cell.
It is well known that RAS family members have multi-
le other targets, such as PI(3)K and RalGDS; these may
xert more prominent oncogenic effects in certain tumor
ubtypes, thereby reducing the requirement for MAPK acti-
ation. Hence, single-agent therapeutic strategies may prove
nsufficient in RAS mutant tumors. Instead, direct RAS
nhibitors or combinatorial strategies may be required.
Recently, an oral MEK inhibitor (MEK162) was tested
n patients with metastatic melanoma harboring BRAF or
RAS mutations with encouraging results in NRAS mutated
atients [88]. In preclinical models MEK162 inhibited
rowth of NRAS-mutated and Val600Glu BRAF-mutated
elanoma in studies that used in vitro and in vivo models
89].
However, the response rate was reported in only 20% ofatients and only in 10% of this population the response
as confirmed. Furthermore, the median progression-free
urvival (PFS) was 3.7 months and the median duration of
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RAS has been consistently described as a mechanism of16 M. Mandalà et al. / Critical Reviews i
esponse was 7.6 weeks [88]. These data clearly indicate that
ost of the patients rapidly develop resistance to the MEK
nhibitor.
A two-arm, randomized, prospective, open-label, multi-
enter, phase III study to compare the efficacy and safety of
EK162 (45 mg bis in die) versus dacarbazine (1000 mg/m2
V every 3 weeks) in patients with advanced (Stage IIIC)
nresectable or metastatic (Stage IV) NRAS Q61 mutation-
ositive cutaneous melanoma is currently underway. The
rimary end point of the study is progression-free survival,
hile secondary end point is overall survival (“NEMO trial”
CT01763164).
Another second generation MEK inhibitor, selumetinib,
emonstrated marked inhibition of pERK, either in cell lines
arboring BRAF mutations as well as in those harboring
RAS mutations [90].
A randomized phase II study comparing the MEK
nhibitor Pimasertib (AS703026) with dacarbazine in pre-
iously untreated subjects with N-Ras mutated locally
dvanced or metastatic malignant cutaneous melanoma is
urrently under way (NCT01693068).
At the time of the publication of this manuscript there are
o randomized clinical trials comparing MEK162 with other
EK inhibitors in NRAS mutated melanoma patients.
Recently the development of small molecules that irre-
ersibly bind to a common oncogenic mutant, K-Ras(G12C)
as been reported [91]. These compounds rely on the
utant cysteine for binding and therefore do not affect the
t protein. These inhibitors to K-Ras(G12C) subvert the
ative nucleotide preference to favor GDP over GTP and
mpairing binding to Raf. These findings are relevant since
hey reveal, for the first time, a new allosteric regulatory
ite on Ras that is targetable in a mutant-specific man-
er.
A subgroup of melanomas with RAS dependence is those
ith low-activity.
BRAF mutations, such as those found at positions 466,
64 and 597. Cell lines with low-activity BRAF mutations
how an impaired activation of MAPK signaling in isolated
inase assays and often harbor concurrent NRAS mutations
t positions 12 and 13. It cannot be excluded that NRAS
elanoma cells with low activity mutant BRAF may partially
xplain the sensitivity of a subgroup of NRAS melanoma cells
o MEK inhibitors.
In accordance with this hypothesis, Dahlman et al. per-
ormed an analysis of BRAF exon 15 in 49 tumors with lack
f BRAFV600 mutation and showed that 2 (4%) harbored
597 mutations and other 2 BRAF D594 and K601 muta-
ions [92]. In vitro signaling induced by L597 mutants was
uppressed by MEK inhibition. A patient with BRAF L597S
utant metastatic melanoma responded significantly to treat-
ent with the MEK inhibitor, TAK-733. Collectively, these
ata show clinical significance response to BRAF(L597)
utations in melanoma.
The focus of indirect RAS inhibition has then shifted to
nterfere with the complex network of activated downstream
r
s
ology/Hematology 92 (2014) 107–122
ascades such as the MAPK, phosphoinositol 3-kinase
PI3K), phospholipid C (PLC), RalGEF.
Posch et al. evaluated the sensitivity of RAS mutated
elanoma cells and xenografts to MEK and PI3K inhibitors
93]. NRAS mutated cells were more sensitive to MEK
nhibition compared with the PI3K/mTOR cascade inhibi-
ion. Combined targeting of MEK and PI3K was superior to
EK and mTOR inhibition in all NRAS mutant melanoma
ell lines, suggesting that PI3K signaling is more important
or cell survival in NRAS mutant melanoma when MEK
s inhibited. However, targeting of PI3K/mTOR in com-
ination with MEK inhibitors is necessary to effectively
bolish growth of NRAS mutant melanoma cells in vitro and
egress xenografted NRAS mutant melanoma. In this model
EK and PI3K/mTOR inhibition was synergistic. These
esults indicate that combined targeting of the MEK/ERK
nd PI3K/mTOR pathways has antitumor activity and could
e a valid option in the treatment of NRAS mutant melanoma,
or which there are currently no effective therapies.
Finally, Johnson et al. reported that patients with
RAS mutated metastatic melanoma achieve increased clin-
cal benefit from immunotherapy compared to those with
RAF/NRAS wt [94].
These data suggest that NRAS mutation status may be
 biomarker of response to immunotherapy in metastatic
elanoma and that molecularly targeted immunotherapy may
e feasible. However a larger, prospective analysis is neces-
ary to validate and expand on these results, including those
ith BRAF mut and KIT mut metastatic melanoma to draw
rm conclusions.
Overall, the above data suggest that: (i) a subgroup of
RAS mutated melanoma may be sensitive to MEK inhibi-
ion but in most cases resistance rapidly occur; (ii) a subgroup
f NRAS mutated melanoma harbor low activity BRAF
utation, and the meaning of these mutations should be fur-
her investigated; (iii) single-agent therapeutic strategies may
rove insufficient in RAS mutant tumors. Instead, combina-
orial strategies may be required to overcome resistance.
.  NRAS  as  a  mechanism  of  resistance  to  BRAF
nhibitors in  melanoma
A high percentage of patients with BRAFV600E mutant
elanomas respond to selective RAF inhibitors but resistance
ventually emerges.
Unlike what happens in other tumors where additional
utations eventually occur in the target (EGFR in non-small
ell lung cancer, c-KIT in GISTs, BCR-ABL in chronic
yeloid leukemia) the early evidence from direct sequenc-
ng of BRAF exons suggests that new point mutations are not
vident and that BRAFV600E persists.esistance to BRAF inhibitors. It is well known that there is a
witch in RAF isoform usage depending on whether BRAF
r RAS is mutated (Table 3) [95–101]. In melanocytes in
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Table 3
Resistance to BRAF inhibitors.
Resistance to BRAF inhibitors
Author Patients with acquired
resistance to therapy no.
Drug Mechanism of resistance NRAS acquired
mutations patients no. (%)
Nazarian (2010) [95] 12 Vemurafenib NRAS codon 61
mutations
PDGFRB overexpression
1 (8.3%)
Trunzer (2013) [96] 13 Vemurafenib Increased pERK levels
MEK1 mutations
NRAS codon 61
mutations
3 (23%)
McArthur (2011) [97] 11 Vemurafenib NRAS codon 61
mutations
1 (9.09%)
Poulikakos (2011) [98] 19 Vemurafenib Increased RAS-GTP
levels
Increased
RAS-independent RAF
dimerization
6 (31.6%)
Wagle (2014) [99] 5 Dabrafenib
Trametinib
Mutation in MEK2
BRAF splice isoform
BRAF amplification
5 (100%)
Van Allen (2014) [100] 30 Vemurafenib
Dabrafenib
MAPK pathway
Alterations
MEK1 Mutations
MEK2 Mutations
MIFT Amplification
23/45 (51%)
Rizos (2014) [101] 38 Mutation in MEK2
Mutation in MEK1
Mutation in NRAS
Mutation in AKT
BRAF splice isoform
3 (8%)
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(hich BRAF is mutated, BRAF is primarily responsible for
ignaling to MEK and ERK. In presence of RAS mutation
n excessive ERK signaling through BRAF and in general
APK activation would induce cell cycle arrest or senes-
ence through transcriptional up-regulation of proteins such
s p21, p27, and p16INK4A [102]. To avoid this, the cells
witch to CRAF, which provides weaker signaling and is
ompatible with tumor progression.
Nazarian et al. demonstrated that high levels of activated
-RAS resulting from mutations lead to significant MAPK
athway reactivation upon BRAF inhibitor treatment [95]. In
 series of elegant experiments, knockdown of NRAS reduced
rowth of the respective BRAF inhibitors resistant cells.
n the opposite, overexpression of N-RAS conferred BRAF
nhibitor resistance to BRAF inhibitor sensitive parental cell
ines.
Recently, Su et al. used cell lines to establish BRAFV600E
elanoma clones with acquired resistance to a BRAF
nhibitor [103]. The authors confirmed that no second-site
utations could be identified in the BRAF coding sequence.
n this model, resistance correlated with increased levels of
AS-GTP, and sequencing of RAS genes revealed a rare acti-
ating mutation in KRAS, resulting in a K117N change in
he KRAS protein. Elevated levels of CRAF and phospho-
ylated AKT were also observed. Interestingly, combination
r
t
cBRAF amplification
reatment with BRAF inhibitor and either a MEK inhibitor
r an AKT inhibitor synergistically inhibited proliferation of
esistant cells. These data support clinical studies in which
ombination therapy with other targeted agents are being
trategized to overcome resistance.
Trunzer et al. [96] evaluated serial biopsies to study
hanges in mitogen-activated protein kinase (MAPK)
ignaling, cell-cycle progression, and factors causing intrin-
ic or acquired resistance by immunohistochemistry, DNA
equencing, or somatic mutation profiling to a BRAF
nhibitor within the BRIM 2 study [104]. In this study 3/13
atients had NRASQ61K co-occurring mutations in tumor
amples taken at progression. Combining these findings with
hose previously reported by Nazarian [95] and McArthur
97], among 36 patients analyzed, five patients (14%) had an
RAS mutation in a progressive lesion. This further supports
he hypothesis by Nazarian et al. [95] that the NRAS  mutation
s one mechanism of escape from vemurafenib therapy.
Overall, the above reported data suggest that: (1) A con-
omitant baseline mutation in the upstream NRAS oncogene
s rare but may result in early lack of clinical benefit to BRAFi;
2) RAS mutation is a common mechanism of acquired
esistance; (3) whether a combination therapy with other
argeted agents could overcome resistance remains to be elu-
idated.
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Table 4
RAS target in locally advanced or metastatic melanoma: ongoing clinical trials (www.clinicaltrials.gov accessed January 26, 2014).
Drug Phase Trial Disease(s) Primary outcome measures
Monotherapy non-randomized
MEK162 II NCT01320085 BRAF or NRAS
Mutated melanoma
ORR
RAF265 II NCT00304525 Melanoma MTD
DLT
Association mutations in
NRAS/clinical response (◦)
Selumetinib (AZD6244) II NCT00866177 BRAF or NRAS
Mutated melanoma
Anti-tumor response
Monotherapy randomized
Pimasertib versus dacarbazina II NCT01693068 NRAS mutated melanoma PFS
MEK162 versus dacarbazine III NCT01763164 NRAS mutated melanoma PFS
AZD6244 versus temozolamide II NCT00338130 Melanoma PFS
ORR*
TTD
Duration of response
Assessment of the efficacy of
AZD6244 versus
temozolomide BRAF or
NRAS MM patients (◦)
Combination therapy non-randomized
BKM120 + MEK162 I NCT01363232 EGFR mutant NSCLC in PD
on EGFR inhibitors
Triple negative breast cancer
Pancreatic cancer
CRC
Melanoma
NSCLC, with KRAS, NRAS,
and/or BRAF mutations
DLT
Trametinib
(GSK1120212) + GSK2141795
II NCT01941927 BRAF wt melanoma ORR* in patients with either
mutated NRAS or wt
NRAS/wt BRAF M
RAF inhibitor (BMS-
908662) + immunotherapy
(ipilimumab)
I NCT01245556 Melanoma Toxicity
PD will be assessed by
evaluating markers of
RAS/RAF pathway activity
(◦)
PI3K/mTOR inhibitor
BEZ235 + MEK1/2 inhibitor
MEK162
Ib NCT01337765 EGFR mutant NSCLC in PD
on EGFR inhibitors
Triple negative breast cancer
Pancreatic cancer
Colorectal cancer
Melanoma
NSCLC
Other advanced solid tumors
with KRAS, NRAS, and/or
BRAF mutations
Incidence of DLT
LEE011 + MEK162 Ib NCT01781572 NRAS mutated melanoma Incidence of DLT
ORR*
M pe; NR
T  rate; C
a
a
d
t
t
p
6
hTD: maximum tolerated dose; EAS: ectopic ACTH secreting; wt: wild ty
TD: time to death; DLT: dose limiting toxicity; ORR*: objective response
The importance of RAS in melanoma deserves clinical
nd biological investigation to optimize treatment of locally
dvanced and metastatic melanoma. Although, in the last two
ecades, progress has been slow, there are now a variety of
herapeutic strategies that are primed for clinical investiga-
ion. Table 4 summarizes ongoing trials in which RAS, and
referentially NRAS, has been selected as a target.
t
m
a: not reported; ORR: overall response rate; PFS: progression free survival;
RC: colorectal cancer; (◦): secondary outcome measures.
.  Future  directions
Thirty years of basic, clinical and translational research
ave produced a large amount of knowledge pertaining to
he RAS oncogene family (Fig. 4). The prevalence of RAS
utations, but also the high number of RAS activators
nd effectors identified in mammalian cells place the RAS
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Fig. 4. Timeline of key advances in NRAS clinical and translational research. (a) Harvey et al. (1964) [97]; (b) Kirsten et al. (1970) [98]; (c) Shih et al. (1980)
[99]; (d) Chang et al. (1982) [2,3], (e) Der et al. (1982) [4], (f) Parada et al. (1982) [5], (g) Santos et al. (1982) [100], (h) Milburn et al. (1990) [103]; (i) Pai
e 9]; (l) V
[  al. (20
P
p
e
i
m
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1
2
3
4
R
O
L
R
Rt al. (1990) [102]; (j) Boguski et al. (1993) [101]; (k) Moodie et al. (1993) [
12]; (o) Chin et al. (1999) [22]; (p) Solit et al. (2006) [86]; (q) Nazarian et
osch et al. (2013) [89].
roteins at the crossroads of several signaling networks. Nev-
rtheless, this extensive knowledge has not yet translated
nto clinically effective therapies for melanomas expressing
utant forms of RAS.
As RAS is mutated in 15–20% of melanomas, priority
ctions are needed:
. Future studies should focus on co-extinction strategies
other than reinforcing inhibition of MAPK signaling.
. Inhibition of the activated downstream cascades including
MAPK, PI3K, PLC, RAL should be pursued in preclinical
and early phase clinical studies.
. Most of the downstream targets are not tumor specific
therapies and bear the risk of severe side effects. Hence,
well-designed clinical studies with appropriate phar-
macokinetics and pharmacodynamic end point between
combination therapies are needed.
. MEK inhibitors as monotherapy should be validated in
prospective, randomized phase III studies.ojtek et al. (1993) [10]; (m) Warne et al. (1993) [11], (n) Zhang et al. (1993)
10) [90]; (r) Whitwam et al. (2007) [37]; (s) Ascierto et al. (2013) [87], (t)
eviewers
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